Vitamin D Supplementation in Patients With Diabetes Mellitus Type 2 (DIMENSION)
Vitamin D Supplementation in Patients With Diabetes Mellitus Type 2 and Low 25(OH)D Concentrations: Does it Help to Improve Endothelial Function-The DIMENSION TRIAL
Background and Objectives :
The presence of vitamin D deficiency in patients with type 2 diabetes mellitus (T2DM) is associated with an increased risk of cardiovascular disease (CVD). We aim to see whether supplementation of vitamin D in these patients helps to improve the endothelial function (EF) a surrogate marker of CVD risk.
Hypothesis: Vitamin D supplementation in patients with T2DM and low serum 25(OH) D concentrations (<30ng/ml) will improve EF as measured by the Endo-PAT machine by 0.4 units (30% improvement over baseline) and/or will result in a increase of EPCs (CD133+/KDR+) and CD45dim CD34+/KDR.
The investigators will test this hypothesis by comparing 2 groups of T2DM patients randomized to placebo or vitamin D3 for 16 weeks.
Methods:
This is a 16 weeks trial in which 120 T2DM patients will be screened with the aim to recruit 60 T2DM patients with vitamin D deficiency or insufficiency. Out of these 60 patients , 30 patients will be started on vitamin D supplementation and 30 patients will be given a matched placebo. Endothelial function (EF) will be checked before and after supplementation to see a change in EF.
Significance of Project:
If this study shows a significant improvement of EF, it would justify larger scale studies to show that vitamin D supplementation in patients with T2DM mitigates CVD risk and vitamin D supplementation in patients with T2DM and vitamin D deficiency to improve CVD risk.
調査の概要
詳細な説明
Overall Aims: Type 2 Diabetes Mellitus (T2DM) is increasingly more prevalent in Singapore and is a high cardiovascular diseases (CVD) risk factor (1,2). The presence of low serum 25(OH)D concentrations (<30ng/ml) has also been classified as an independent predictor of CVD(3,4) and has been seen to be more prevalent in T2DM (5-7). We aim to see whether replacement with vitamin D in these patients helps to mitigate CVD risk. Since endothelial dysfunction is one of the earliest manifestations of CVD and is a very robust surrogate marker, we aim to measure the endothelial function (EF) before and after vitamin D supplementation to evaluate for beneficial impact on this endpoint.
Specific Aims: Although, there are some small scale studies done with a single high dose replacement of vitamin D2/D3, no studies have been done using regular daily supplementation with vitamin D3 and with measurement of EF using the Endo-PAT machine or measurement of endothelial progenitor cells (EPCs).We are doing this pilot study to see whether replacement with vitamin D results in an improvement of EF as measured using the Endo-PAT and estimation of EPCs and some biomarkers as independent established surrogate markers of CVD risk. The estimation of endothelial progenitor cells has been proposed as a surrogate marker of vascular dysfunction and is known to be reduced in patients with cardiovascular risk factors (8). The no. of circulating endothelial cells (CECs) and endothelial microparticles have been seen to be elevated in patients with cardiovascular risk factors and DM and has also been proposed as a effective surrogate marker. We aim to quantify the no. of endothelial progenitor cells (EPCs) staining positive for CD133+/KDR (kinase insert domain-containing receptor),CD34+/KDR and CD45dim CD34+/KDR , CECs (CD 146+/CD45- ) and EMPs derived from endothelial progenitors (CD45-/CD146+/CD34+/CD117+) and from mature endothelial cells (CD45-/CD146+/CD34+/CD117-).using flow cytometry.
Primary Hypothesis:
Vitamin D supplementation in patients with T2DM and low serum 25(OH) D concentrations (<30ng/ml) will improve EF as measured by the Endo-PAT machine by 0.4 units (30% improvement over baseline) and/or will result in a increase of EPCs (CD133+/KDR+) and CD45dim CD34+/KDR. The investigators will test this hypothesis by comparing 2 groups of T2DM patients randomized to placebo or vitamin D3 for 16 weeks.
Secondary Objectives:
To explore the prevalence of low serum 25(OH) D concentrations (<30ng/ml) in T2DM patients and evaluate the difference in the EF in the two groups. To see whether vitamin D supplementation helps to further improve other parameters such as biomarkers, blood pressure, BMI, urine albumin-to-creatinine ratio (ACR), lipid profile of T2DM patients.
研究の種類
入学 (実際)
段階
- フェーズ 4
連絡先と場所
研究場所
-
-
-
Singapore、シンガポール、308433
- Tan Tock Seng Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Subjects with Type 2 Diabetes Mellitus
- HbA1c : 6.0-10.0%
- Male of female aged 21-80 years
- Stable Diabetes, blood pressure and hyperlipidemia medications (a 25% dose adjustment is allowed) in the last three months
- Baseline serum 25(0H)D concentration <30ng/ml for randomisation
Exclusion Criteria:
- Baseline serum 25(OH)D concentration >30ng/ml
- Baseline HbA1c>10.1%
- Baseline hypercalcemia (Ca>2.58 mmol/L)
- Known case of Primary Hyperparathyroidism
- Known to be on bisphosphonates
- Known to be on Vitamin D supplementation of 1000 units daily or more in the last one year.
- Chronic renal failure with eGFR<30ml/min
- Known to have cirrhosis of the liver or transaminitis with ALT/AST >3X ULN
- Patients with h/o sarcoidosis, renal calculi or any malignancy
- Patients on current treatment for tuberculosis
- Pregnancy and Lactation
- Women of childbearing potential not taking effective contraceptive measures.
- Patients on long term glucocorticoids or anti-retroviral drugs
- Patients on orlistat or other over the counter preparations that claim to block fat absorption.
- A change in the type of medications for hypertension, diabetes mellitus and hyperlipidemia in the last three months
- Patients who have undergone any form of bariatric surgery
- Patients known to have any malabsorption disorders
- Patients known to have osteoporosis or of baseline BMD scan shows osteoporosis as T score <-2.5SD (for randomisation)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
プラセボコンパレーター:プラセボ錠剤
|
Placebo pill supplied by oneNine 57 imported to Singapore with approval and import licence from HSA.
他の名前:
|
アクティブコンパレータ:Vitamin D supplementation
Vitamin D3 tablets (cholecalciferol)
|
Vitamin D3 marketed by oneNine57
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Endothelial function as assessed by the reactive hyperemia index and endothelial progenitor cells
時間枠:16 weeks
|
Endothelial function will be tested by using the EndoPAT machine which measures the reactive hyperemia index and by estimating the no. of endothelial progenitor cells in the peripheral blood by flow cytometry.
|
16 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Markers of endothelial cell activation and thrombogenesis
時間枠:16 weeks
|
Biomarkers measured include hsCRP, e-selectin,von-willebrand factor(vWF)
|
16 weeks
|
No. of circulating endothelial cells and endothelial microparticles
時間枠:16-20 weeks
|
The no. of circulating endothelial cells and endothelial microparticles will be estimated before and after intervention.
|
16-20 weeks
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Rinkoo Dalan, MBBS, FRCP、Tan Tock Seng Hospital
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
ビタミンD欠乏症の臨床試験
-
University of UlsterDairy Council for Northern Ireland; Agri-food & Biosciences Institute; Center for Nutrition and...完了
-
University of UlsterNorthern Ireland Executive; HSC Public Health Agency完了
-
University of Eastern Finland完了ビタミン D 受容体標的遺伝子の発現 | 血清25(OH)D濃度フィンランド
-
University of Eastern FinlandDSM Nutritional Products, Inc.完了ビタミン D 受容体標的遺伝子の発現 | 血清25(OH)D濃度フィンランド
-
Horopito LimitedAtlantia Food Clinical Trials完了
Vitamin D supplementationの臨床試験
-
Johns Hopkins UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)完了
-
GlaxoSmithKline完了
-
University of AarhusNovo Nordisk A/S; Aarhus University Hospital; AP Moeller Foundation; Danish Diabetes Academy募集
-
Johns Hopkins UniversityNational Institute of Allergy and Infectious Diseases (NIAID)まだ募集していません
-
Daewoong Pharmaceutical Co. LTD.まだ募集していません
-
University Medical Center GroningenMaastricht University Medical Center; UMC Utrecht; Academisch Medisch Centrum - Universiteit van... と他の協力者完了